Oral tofacitinib helps in alopecia areata in children
A recent study in the journal Pediatric Dermatology showed oral tofacitinib to be clinically effective and well-tolerated in the majority of pediatric patients with alopecia areata (AA).
Alopecia areata is an autoimmune disorder characterized by the loss of hair, often in well-demarcated areas. While its pathogenesis is not well understood, it is known that CD8 T cell-mediated destruction of the hair follicle occurs. Several therapies have been utilized with variable results but there is no definitive therapy for AA. Oral tofacitinib, a JAK inhibitor, has been shown to be effective and well-tolerated for the treatment of AA in adults. However, few studies have examined the clinical efficacy and tolerability of oral tofacitinib for the treatment of pediatric AA.
For more details, check out the full story on the link below:
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)